Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022568 (
keratitis
)
5,133
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Members of the genus Acanthamoeba are facultative pathogens of humans, causing a sight-threatening
keratitis
and a fatal encephalitis. We have targeted
myosin-IC
by using small interfering RNA (siRNA) silencing as a therapeutic approach, since it is known that the function of this protein is vital for the amoeba. In this work, specific siRNAs against the Acanthamoeba
myosin-IC
gene were developed. Treated and control amoebae were cultured in growth and encystment media to evaluate the induced effects after
myosin-IC
gene knockdown, as we have anticipated that cyst formation may be impaired. The effects of
myosin-IC
gene silencing were inhibition of cyst formation, inhibition of completion of cytokinesis, inhibition of osmoregulation under osmotic stress conditions, and death of the amoebae. The finding that
myosin-IC
silencing caused incompletion of cytokinesis is in agreement with earlier suggestions that the protein plays a role in cell locomotion, which is necessary to pull daughter cells apart after mitosis in a process known as "traction-mediated cytokinesis". We conclude that
myosin-IC
is a very promising potential drug target for the development of much-needed antiamoebal drugs and that it should be further exploited for Acanthamoeba therapy.
...
PMID:Evaluation of Acanthamoeba myosin-IC as a potential therapeutic target. 2446 84